Charles River Laboratories International Stock News

Science 37 (NASDAQ:SNCE) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Profitability This table compares Science 37 and Charles River Laboratories Internationals net margins, return []

Charles River's (CRAI) third-quarter 2021 earnings and revenues improve year over year.

The company's stock dropped nearly $75 a share over the course of the week, rattling investors.

Charles River Laboratories International Inc (NYSE: CRL) Q3 sales increased 20.5% Y/Y to $895.9 million, missing the consensus of $903.20 million. Acquisitions contributed 5.9% to consolidated third

Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.

Charles River Laboratories International, Inc.'s (CRL) CEO Jim Foster on Q3 2021 Results - Earnings Call Transcript

Charles River (CRL) delivered earnings and revenue surprises of 5.06% and -1.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River Laboratories has come off its recent highs, but that doesn't make the company cheap.CRL is trading at about 30-33 times its anticipated 2021 free cash flow result.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #3Q2021--Charles River Laboratories schedules Third-Quarter 2021 earnings release and conference call

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announces two divestitures.

Consecutive better-than-expected top- and bottom-line performances, and an encouraging 2021 guidance have been aiding Charles River (CRAI) stock.

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.